We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Local Chemotherapy of Maduromycosis Caused by Monosporium apiospermum

C. Edward Buckley III, MD; Robert S. Mathews, MD; J. Andrew Grant, MD; William G. Edwards, MD; H. Stewart Neilsen, PhD
Arch Intern Med. 1969;124(6):748-753. doi:10.1001/archinte.1969.00300220100019.
Text Size: A A A
Published online


Localized deep-seated fungus infections are only occasionally seen in the temperate climate of this country. Infection with Monosporium apiospermum is especially uncommon, but does occur.1 Unlike mycetomatous disease caused by other fungi, infections with M apiospermum respond poorly to chemotherapy.1,2 Destructive excision or amputation of involved tissues is usually necessary.

A patient, who had maduromycosis of the foot caused by M apiospermum but had refused amputation, provided a unique opportunity to evaluate the effectiveness of a new therapeutic approach to localized fungus infection: high dosage, local, parenterally administered chemotherapy. The relative effectiveness and safety of two different antifungal drugs, and the usefulness of dimethyl sulfoxide (DMSO) as a vehicle for local parenterally administered therapy were explored in this patient. The chronicity of the infection and complicating bacterial osteomyelitis precluded eventual salvage of a functional foot. Nevertheless, the studies accomplished confirmed the effectiveness of local parenterally administered therapy and


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.